Ginkgo Bioworks (DNA) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ginkgo Bioworks (DNA) has outperformed MannKind (MNKD) over the past year, losing 29.5% versus a loss of 37.1%. Over five years, MNKD leads with a -32.8% price change compared with -97.6% for DNA. MannKind is the larger company by market cap ($1.09 billion vs $870.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | MNKD |
|---|---|---|
| Share price | $12.93 | $3.38 |
| Market cap | $870.59M | $1.09B |
| 1-day change | +14.03% | -1.32% |
| YTD return | +36.46% | -39.68% |
| 1-year return | -29.52% | -37.13% |
| 5-year return | -97.62% | -32.81% |
| Forward P/E | — | 26.47 |
| EPS (TTM) | $-5.06 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $6.51 |
| 52-week low | $5.37 | $2.23 |
| Distance from 52-week high | -29.04% | -48.16% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -45.85% | +132.30% |
| Average volume | 1.80M | 4.50M |
| Shares outstanding | 55.38M | 321.54M |
| Employees | 485 | 591 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
DNA vs MNKD FAQ
Which is bigger, Ginkgo Bioworks or MannKind?
MannKind (MNKD) is larger, with a market capitalization of $1.09B compared with $870.59M for Ginkgo Bioworks (DNA).
Which stock has performed better over the past year, DNA or MNKD?
DNA returned -29.52% over the past 12 months, compared with -37.13% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and MannKind in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Ginkgo Bioworks and Biotechnology: Pharmaceutical Preparations for MannKind.